CA2121716C - Method and medical agent for diagnosis of arthritis - Google Patents

Method and medical agent for diagnosis of arthritis Download PDF

Info

Publication number
CA2121716C
CA2121716C CA002121716A CA2121716A CA2121716C CA 2121716 C CA2121716 C CA 2121716C CA 002121716 A CA002121716 A CA 002121716A CA 2121716 A CA2121716 A CA 2121716A CA 2121716 C CA2121716 C CA 2121716C
Authority
CA
Canada
Prior art keywords
methyl
amino
chlorin
tetrapyrrole
acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002121716A
Other languages
English (en)
French (fr)
Other versions
CA2121716A1 (en
Inventor
Katsuo Aizawa
Yukari Kuroiwa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eneos Corp
Original Assignee
Nippon Oil Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Oil Corp filed Critical Nippon Oil Corp
Publication of CA2121716A1 publication Critical patent/CA2121716A1/en
Application granted granted Critical
Publication of CA2121716C publication Critical patent/CA2121716C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002121716A 1993-04-22 1994-04-20 Method and medical agent for diagnosis of arthritis Expired - Lifetime CA2121716C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP12097793A JP3565442B2 (ja) 1993-04-22 1993-04-22 哺乳類の関節炎の診断剤および／または治療剤
JP5-120977 1993-04-22

Publications (2)

Publication Number Publication Date
CA2121716A1 CA2121716A1 (en) 1994-10-23
CA2121716C true CA2121716C (en) 2008-01-08

Family

ID=14799730

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002121716A Expired - Lifetime CA2121716C (en) 1993-04-22 1994-04-20 Method and medical agent for diagnosis of arthritis

Country Status (7)

Country Link
US (2) US5430051A (show.php)
EP (1) EP0629409A1 (show.php)
JP (1) JP3565442B2 (show.php)
KR (1) KR100254135B1 (show.php)
CN (1) CN1074665C (show.php)
CA (1) CA2121716C (show.php)
TW (1) TW259706B (show.php)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807881A (en) 1992-05-27 1998-09-15 Quadra Logic Technologies, Inc. Method for selectively reducing activated leukocyte cell population
AU6031096A (en) * 1995-06-05 1996-12-24 Duke University Nitrosylated and nitrated superoxide oxidants and reductants
WO1998015273A1 (en) * 1996-10-10 1998-04-16 The General Hospital Corporation Photodynamic therapy for the treatment of osteoarthritis
CA2270558C (en) * 1996-11-06 2006-08-15 Meiji Seika Kaisha, Ltd. Treatment of autoimmune diseases by photochemotherapy
US5952664A (en) * 1997-01-17 1999-09-14 Imaging Diagnostic Systems, Inc. Laser imaging apparatus using biomedical markers that bind to cancer cells
AU747753B2 (en) * 1997-08-05 2002-05-23 Meiji Seika Kaisha Ltd. Immunosuppression by photochemotherapy
EP1131100B1 (en) * 1999-01-15 2003-03-12 Light Sciences Corporation Therapeutic compositions for metabolic bone disorders or bone metastases comprising a photosensitizer and a bisphosphonate
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
WO2000041726A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
CA2395567A1 (en) * 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
WO2004002476A2 (en) 2002-06-27 2004-01-08 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
US7053210B2 (en) 2002-07-02 2006-05-30 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
EP1594875A4 (en) 2003-01-16 2007-07-11 Technomart Co Ltd porphyrin derivatives
US10376711B2 (en) * 2003-03-14 2019-08-13 Light Sciences Oncology Inc. Light generating guide wire for intravascular use
CN2885311Y (zh) 2006-01-18 2007-04-04 郑成福 经尿道光动力疗法前列腺治疗仪
US20080269846A1 (en) * 2003-03-14 2008-10-30 Light Sciences Oncology, Inc. Device for treatment of blood vessels using light
WO2007103427A2 (en) * 2006-03-06 2007-09-13 Wang Xiang H Medical use of bilirubin and its structural analogues
US8057464B2 (en) * 2006-05-03 2011-11-15 Light Sciences Oncology, Inc. Light transmission system for photoreactive therapy
KR101456839B1 (ko) * 2006-06-30 2014-11-03 유로-셀티큐 에스.에이. 광활성제 조성물 및 광활성제의 제조 방법
EP2182835B1 (en) * 2007-08-14 2019-06-19 mivenion GmbH Device and procedure for the diagnosis or diagnostic preparation and/or therapy monitoring of inflammatory diseases such as rheumatoid arthritis
CN101426268B (zh) * 2007-11-02 2010-08-25 大唐移动通信设备有限公司 导频资源分配方法、系统和设备
WO2009065065A1 (en) * 2007-11-15 2009-05-22 Ceramoptec Industries, Inc. Pegylated liposomal formulations for photodynamic treatment of inflammatory diseases
CN107987081B (zh) * 2016-10-26 2019-12-06 刘辉 一种二氢卟吩e6衍生物及其药学上可接受的盐、其制备方法和应用
US20230330138A1 (en) * 2022-04-14 2023-10-19 Creative Medical Technologies, Inc. Treatment of cartilage degeneration using myeloid suppressor cells and exosomes derived thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3102891A (en) * 1959-11-16 1963-09-03 Elmer A Allen New porphyrinic and chlorophyllic compositions and process therefor
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4693885A (en) * 1984-07-18 1987-09-15 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
US4675338A (en) * 1984-07-18 1987-06-23 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
US4656186A (en) * 1985-04-30 1987-04-07 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
US5066274A (en) * 1985-04-30 1991-11-19 Nippon Petrochemicals Company, Ltd. Tetrapyrrole therapeutic agents
US4977177A (en) * 1985-04-30 1990-12-11 Nippon Petrochemicals Company, Ltd. Tetrapyrrole polyaminomonocarboxylic acid therapeutic agents
US5004811A (en) * 1987-12-24 1991-04-02 Nippon Petrochemicals Company, Ltd. Tetrapyrrole aminocarboxylic acids
US5028594A (en) * 1988-12-27 1991-07-02 Naxcor Use of photodynamic compositions for cytotoxic effects
US4997639A (en) * 1989-11-27 1991-03-05 Nippon Petrochemicals Company, Limited Method for detecting cholesterol deposited in bodies of mammals
JP3154742B2 (ja) * 1991-04-30 2001-04-09 日本石油化学株式会社 哺乳類の動脈硬化症治療剤
PT680365E (pt) * 1992-11-20 2000-07-31 Univ British Columbia Activacao de agentes fotossensibilizadores
US5368841A (en) * 1993-02-11 1994-11-29 The General Hospital Corporation Photodynamic therapy for the destruction of the synovium in the treatment of rheumatoid arthritis and the inflammatory arthritides

Also Published As

Publication number Publication date
CN1074665C (zh) 2001-11-14
CN1099613A (zh) 1995-03-08
US5430051A (en) 1995-07-04
TW259706B (show.php) 1995-10-11
JPH06305961A (ja) 1994-11-01
JP3565442B2 (ja) 2004-09-15
EP0629409A1 (en) 1994-12-21
KR100254135B1 (ko) 2000-05-01
US5567409A (en) 1996-10-22
CA2121716A1 (en) 1994-10-23

Similar Documents

Publication Publication Date Title
US5567409A (en) Method and medical agent for diagnosis of arthritis
US5308861A (en) Therapeutic agent for treating atherosclerosis of mammals
DK168296B1 (da) Fluorescerende mono-, di- eller polyamider af en amino-monocarboxylsyre og en tetrapyrrolforbindelse samt anvendelse af disse til fremstilling af et farmaceutisk præparat til fotodiagnose og/eller fototerapi af tumorer
DK168512B1 (da) Terapeutiske præparater til brug ved fotodiagnose og fototerapi
AU592058B2 (en) New tetrapyrrole therapeutic agents
EP0168832B1 (en) Pharmaceutical composition containing a tetrapyrrole compound as active ingredient and process for the production of the tetrapyrrole compound
US4997639A (en) Method for detecting cholesterol deposited in bodies of mammals
US5283255A (en) Wavelength-specific cytotoxic agents
AU638675B2 (en) Wavelength-specific cytotoxic agents
US5004811A (en) Tetrapyrrole aminocarboxylic acids
US6248734B1 (en) Use of photodynamic therapy for prevention of secondary cataracts
Kessel et al. Porphyrin accumulation by atheromatous plaques of the aorta
DK168690B1 (da) Farmaceutiske præparater til detektion og/eller behandling af pattedyrtumorer
Richter et al. Characterization of benzoporphyrin derivative, a new photosensitizer
US5066274A (en) Tetrapyrrole therapeutic agents
CA2270558C (en) Treatment of autoimmune diseases by photochemotherapy
HUE031075T2 (en) Cationic bacteriochlorophyll derivatives and uses thereof
KR100748908B1 (ko) 포르피린 화합물
JP3718887B2 (ja) ポルフィリン誘導体とその用途
US20050209298A1 (en) Method of photodynamic diagnosis for vascular diseases
CA2199400C (en) Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases
CZ204799A3 (cs) Použití zelených porfyrinů pro výrobu léčiva k ošetřování sekundárního šedého zákalu
MXPA99005399A (en) Use of green porphyrins for the manufacture of a medicament for the treatment of secondary cataracts

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140422